Clinical Trial Update: IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing IX-01 on intravaginal ejaculatory latency time and patient-reported outcomes in men with premature ejaculation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• IX-01

Snippet

Sponsor: Ixchelsis Limited | Conditions: Premature Ejaculation | Phase 2 | Status: COMPLETED | Results posted: 2019-01-24